{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:45:57Z","timestamp":1792755957279,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40265-016-0596-x","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T06:03:06Z","timestamp":1464933786000},"page":"979-987","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":223,"title":["Venetoclax: First Global Approval"],"prefix":"10.1007","volume":"76","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,3]]},"reference":[{"issue":"15","key":"596_CR1","doi-asserted-by":"crossref","first-page":"12862","DOI":"10.18632\/oncotarget.3868","volume":"6","author":"S Besbes","year":"2015","unstructured":"Besbes S, Mirshahi M, Pocard M, et al. New dimension in therapeutic targeting of BCL-2 family proteins. Oncotarget. 2015;6(15):12862\u201371.","journal-title":"Oncotarget."},{"issue":"10","key":"596_CR2","first-page":"698","volume":"12","author":"J Seymour","year":"2014","unstructured":"Seymour J. ABT-199 for chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2014;12(10):698\u2013700.","journal-title":"Clin Adv Hematol Oncol."},{"key":"596_CR3","first-page":"234370","volume":"2014","author":"J Su","year":"2014","unstructured":"Su J, Zhou L, Xia MH, et al. Bcl-2 family proteins are involved in the signal crosstalk between endoplasmic reticulum stress and mitochondrial dysfunction in tumor chemotherapy resistance. Biomed Res Int. 2014;2014:234370.","journal-title":"Biomed Res Int."},{"key":"596_CR4","unstructured":"AbbVie Inc., Genentech Inc. Venclexta\u2122 (venetoclax): US prescribing information. 2016. http:\/\/www.fda.gov . Accessed 21 Apr 2016."},{"key":"596_CR5","unstructured":"US Food and Drug Administration. Venetoclax (Venclexta) tablets. 2016. http:\/\/www.fda.gov . Accessed 2 May 2016."},{"issue":"2","key":"596_CR6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202\u20138.","journal-title":"Nat Med."},{"issue":"1","key":"596_CR7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjh.12457","volume":"163","author":"M Vogler","year":"2013","unstructured":"Vogler M, Dinsdale D, Dyer MJ, et al. ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. Br J Haematol. 2013;163(1):139\u201342.","journal-title":"Br J Haematol."},{"issue":"1","key":"596_CR8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjh.13278","volume":"170","author":"Y Cao","year":"2015","unstructured":"Cao Y, Yang G, Hunter ZR, et al. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015;170(1):134\u20138.","journal-title":"Br J Haematol."},{"issue":"5","key":"596_CR9","doi-asserted-by":"crossref","first-page":"e00178","DOI":"10.1002\/prp2.178","volume":"3","author":"S Ackler","year":"2015","unstructured":"Ackler S, Oleksijew A, Chen J, et al. Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax. Pharmacol Res Perspect. 2015;3(5):e00178.","journal-title":"Pharmacol Res Perspect."},{"issue":"1","key":"596_CR10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","volume":"28","author":"C Touzeau","year":"2014","unstructured":"Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210\u20132.","journal-title":"Leukemia."},{"issue":"25","key":"596_CR11","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Peirs","year":"2014","unstructured":"Peirs S, Matthijssens F, Goossens S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124(25):3738\u201347.","journal-title":"Blood."},{"issue":"8","key":"596_CR12","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/leu.2015.99","volume":"29","author":"L Li","year":"2015","unstructured":"Li L, Pongtornpipat P, Tiutan T, et al. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1. Leukemia. 2015;29(8):1702\u201312.","journal-title":"Leukemia."},{"issue":"19","key":"596_CR13","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.18632\/oncotarget.1925","volume":"5","author":"TK Ko","year":"2014","unstructured":"Ko TK, Chuah CT, Huang JW, et al. The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget. 2014;5(19):9033\u20138.","journal-title":"Oncotarget."},{"key":"596_CR14","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1038\/bcj.2015.88","volume":"5","author":"DC Phillips","year":"2015","unstructured":"Phillips DC, Xiao Y, Lam LT, et al. Loss in MCL-1 function sensitizes non-Hodgkin\u2019s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015;5:e368.","journal-title":"Blood Cancer J."},{"issue":"9","key":"596_CR15","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, Roderick JE, Glenfield C, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4(9):1074\u201387.","journal-title":"Cancer Discov."},{"issue":"16","key":"596_CR16","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","volume":"21","author":"F Cervantes-Gomez","year":"2015","unstructured":"Cervantes-Gomez F, Lamothe B, Woyach JA, et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 2015;21(16):3705\u201315.","journal-title":"Clin Cancer Res."},{"issue":"5","key":"596_CR17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.13149","volume":"168","author":"X Zhao","year":"2015","unstructured":"Zhao X, Bodo J, Sun D, et al. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2015;168(5):765\u20138.","journal-title":"Br J Haematol."},{"issue":"5","key":"596_CR18","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/leu.2015.350","volume":"30","author":"SM Matulis","year":"2016","unstructured":"Matulis SM, Gupta VA, Nooka AK, et al. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia. 2016;30(5):1086\u201393.","journal-title":"Leukemia."},{"issue":"12","key":"596_CR19","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2013-01-475855","volume":"121","author":"CJ Vandenberg","year":"2013","unstructured":"Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood. 2013;121(12):2285\u20138.","journal-title":"Blood."},{"issue":"1","key":"596_CR20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ccr.2013.06.002","volume":"24","author":"F Vaillant","year":"2013","unstructured":"Vaillant F, Merino D, Lee L, et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell. 2013;24(1):120\u20139.","journal-title":"Cancer Cell."},{"issue":"26","key":"596_CR21","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","volume":"123","author":"V Fresquet","year":"2014","unstructured":"Fresquet V, Rieger M, Carolis C, et al. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood. 2014;123(26):4111\u20139.","journal-title":"Blood."},{"issue":"4","key":"596_CR22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311\u201322.","journal-title":"N Engl J Med."},{"key":"596_CR23","doi-asserted-by":"publisher","unstructured":"Salem AH, Agarwal S, Dunbar M, et al. Effect of low and high fat meals on the pharmacokinetics of venetoclax, a selective first-in-class bcl-2 inhibitor. J Clin Pharmacol. 2016. doi: 10.1002\/jcph.741 .","DOI":"10.1002\/jcph.741"},{"key":"596_CR24","doi-asserted-by":"publisher","unstructured":"Agarwal SK, Hu B, Chien D, et al. Evaluation of rifampin\u2019s transporter inhibitory and CYP3A inductive effects on the pharmacokinetics of venetoclax, a Bcl-2 inhibitor: results of a single- and multiple-dose study. J Clin Pharmacol. 2016. doi: 10.1002\/jcph.730 .","DOI":"10.1002\/jcph.730"},{"key":"596_CR25","unstructured":"Lymphoma Association. Leukaemia and lymphoma - what\u2019s the difference? 2011. http:\/\/www.nhs.uk\/ipgmedia\/national\/Lymphoma%20Association\/Assets\/Leukaemiaandlymphoma-thedifference.pdf . Accessed 2 May 2016."},{"key":"596_CR26","doi-asserted-by":"publisher","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016. doi: 10.1016\/S1470-2045(16)30019-5 .","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"596_CR27","doi-asserted-by":"crossref","unstructured":"Jones JA, Wierda WG, Choi MY, et al. Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib [abstract no. 7519]. In: ASCO Annual Meeting; 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.7519"},{"issue":"23","key":"596_CR28","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood.V126.23.830.830","volume":"126","author":"S Ma","year":"2015","unstructured":"Ma S, Brander DM, Seymour JF, et al. Deep and durable responses following venetoclax (ABT-199\/GDC-0199) combined with rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia: results from a phase 1B study. Blood. 2015;126(23):830.","journal-title":"Blood."},{"issue":"23","key":"596_CR29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood.V126.23.829.829","volume":"126","author":"GA Salles","year":"2015","unstructured":"Salles GA, Boyd TE, Morschhauser F, et al. Updated safety and preliminary efficacy data from a phase 1B study combining venetoclax (GDC-0199, ABT-199) with bendamustine\/rituximab in patients with relapsed\/refractory or previously untreated chronic lymphocytic leukemia [abstract]. Blood. 2015;126(23):829.","journal-title":"Blood."},{"issue":"23","key":"596_CR30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood.V126.23.494.494","volume":"126","author":"IW Flinn","year":"2015","unstructured":"Flinn IW, Brunvand M, Choi MY, et al. Safety and efficacy of a combination of venetoclax (GDC-0199\/ABT-199) and obinutuzumab in patients with relapsed\/refractory or previously untreated chronic lymphocytic leukemia-results from a phase 1b study (GP28331) [abstract]. Blood. 2015;126(23):494.","journal-title":"Blood."},{"issue":"23","key":"596_CR31","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood.V126.23.254.254","volume":"126","author":"JF Gerecitano","year":"2015","unstructured":"Gerecitano JF, Roberts AW, Seymour JF, et al. A phase 1 study of venetoclax (ABT-199\/GDC-0199) monotherapy in patients with relapsed\/refractory non-hodgkin lymphoma [abstract]. Blood. 2015;126(23):254.","journal-title":"Blood."},{"issue":"Suppl 1","key":"596_CR32","first-page":"525","volume":"99","author":"MS Davids","year":"2014","unstructured":"Davids MS, Seymour JF, Gerecitano JF, et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed\/refractory non-hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses [abstract no. S1348]. Haematologica. 2014;99(Suppl 1):525.","journal-title":"Haematologica."},{"issue":"23","key":"596_CR33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/blood.V126.23.255.255","volume":"126","author":"S Vos De","year":"2015","unstructured":"De Vos S, Swinnen L, Kozloff M, et al. A dose-escalation study of venetoclax (ABT-199\/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-hodgkin\u2019s lymphoma [abstract]. Blood. 2015;126(23):255.","journal-title":"Blood."},{"key":"596_CR34","doi-asserted-by":"crossref","unstructured":"Tam CSL, Roberts AW, Anderson MA, et al. The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed\/refractory mantle cell lymphoma: preliminary results of the phase II AIM study [abstract no. 7548]. In: ASCO Annual Meeting; 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.7548"},{"key":"596_CR35","doi-asserted-by":"crossref","unstructured":"Kumar S, Vij R, Kaufman JL, et al. Phase I venetoclax monotherapy for relapsed\/refractory multiple myeloma [abstract no. 8032]. In: ASCO Annual Meeting; 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.8032"},{"key":"596_CR36","doi-asserted-by":"crossref","unstructured":"Moreau P, Chanan-Khan AAA, Roberts AW, et al. Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma [abstract no. 8011]. In: ASCO Annual Meeting; 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.8011"},{"key":"596_CR37","doi-asserted-by":"crossref","unstructured":"Konopleva M, Pollyea DA, Potluri J, et al. A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (AML) [abstract]. Blood. 2014;124(21):118.","DOI":"10.1182\/blood.V124.21.118.118"},{"key":"596_CR38","doi-asserted-by":"crossref","unstructured":"Pollyea DA, Dinardo CD, Thirman MJ, et al. Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients \u226565\u00a0years ineligible for standard induction therapy [abstract no. 7009]. In: ASCO Annual Meeting; 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.7009"},{"key":"596_CR39","doi-asserted-by":"crossref","unstructured":"Lin TL, Strickland SA, Fiedler W, et al. Phase Ib\/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age \u226565 with acute myelogenous leukemia [abstract no. 7007]. In: ASCO Annual Meeting; 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.7007"},{"issue":"Suppl 1","key":"596_CR40","first-page":"321","volume":"99","author":"J Seymour","year":"2014","unstructured":"Seymour J, Roberts A, Stilgenbauer S, et al. Reduction of tumor lysis syndrome (TLS) risk in chronic lymphocytic leukemia (CLL) patients treated with ABT-199 (GDC-0199): results of modifications to dosing schedule and TLS prophylaxis [abstract no. P868]. Haematologica. 2014;99(Suppl 1):321.","journal-title":"Haematologica."},{"key":"596_CR41","unstructured":"U.S. Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). 2016. http:\/\/www.fda.gov . Accessed 29 Apr 2016."},{"key":"596_CR42","doi-asserted-by":"crossref","unstructured":"Mobasher M, Huang J, Elstrom RL, et al. Multicenter, phase III, open-label, randomized study in relapsed\/refractory CLL to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab [abstract no. TPS7120]. In: ASCO Annual Meeting; 2014.","DOI":"10.1200\/jco.2014.32.15_suppl.tps7120"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0596-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-016-0596-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0596-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T11:50:45Z","timestamp":1600689045000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-016-0596-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["596"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0596-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}